VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2022 | Future work on pharmacogenomic testing in migraine

Yi-Chieh Chen, PharmD, Mayo Clinic, Rochester, MN, discusses future work concerning verapamil and pharmacogenomics in treating migraine. Pharmacogenomic testing is far more common in anti-depressants than in migraine-specific therapies. Since many anti-depressants are also used for the preventive treatment of migraine, future work would investigate the pharmacogenomic effects of anti-depressants to produce a larger sample size. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.